Form 4: Indivior CCO Granted 31,380 Restricted Stock Units

Indivior Pharmaceuticals' Chief Commercial Officer, Patrick A. Barry, was granted 31,380 restricted stock units, vesting over three years.

Summary

• Patrick A. Barry, Chief Commercial Officer of Indivior Pharmaceuticals, Inc. (INDV), was granted 31,380 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant was February 10, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in three equal annual installments, with the first installment vesting on February 10, 2027, subject to Mr. Barry's continued service with the Issuer.
• The acquisition price for these securities was $0 per share, which is typical for RSU grants as a form of compensation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices and management's continued alignment with shareholder interests, without indicating any significant new strategic developments or financial performance.

Positives

• The grant of restricted stock units aligns the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• Equity compensation is a standard practice for executive remuneration, reflecting confidence in the executive's continued contribution to the company.

Future Outlook

The vesting schedule of the RSUs indicates a commitment to retaining key management personnel over the next three years, aligning executive incentives with future company performance.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to a Chief Commercial Officer is a common and widely accepted practice in the pharmaceutical industry for executive compensation. This method is used to attract, retain, and motivate key talent by linking their long-term financial interests to the company's stock performance.

Comparison to Industry Standards

• Equity compensation, particularly through RSU grants, is a standard component of executive remuneration packages across the pharmaceutical and broader corporate sectors. Companies like Pfizer, Johnson & Johnson, and Merck routinely utilize similar mechanisms to incentivize their leadership.
• The three-year vesting schedule is typical for such grants, providing a balance between immediate reward and long-term retention, comparable to practices observed at peer companies.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with long-term shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Employees: This type of executive compensation can signal stability in leadership and a commitment to retaining key personnel, potentially boosting morale.

Next Steps

• The RSUs will vest in three equal annual installments, with the first vesting on February 10, 2027, and subsequent installments on the same date in 2028 and 2029, contingent on continued service.

Key Dates

Keywords

Indivior Pharmaceuticals, INDV, Restricted Stock Units, RSU Grant, Equity Compensation, Insider Transaction, Executive Compensation, Patrick A. Barry, Chief Commercial Officer